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STUDY PROTOCOL

TRIALS
Open Access

Wordless intervention for epilepsy in learning
disabilities (WIELD): study protocol for a
randomized controlled feasibility trial
Marie-Anne Durand1,2*, Bob Gates3, Georgina Parkes4, Asif Zia4, Karin Friedli1, Garry Barton5, Howard Ring6,
Linda Oostendorp1 and David Wellsted1

Abstract
Background: Epilepsy is the most common neurological problem that affects people with learning disabilities. The
high seizure frequency, resistance to treatments, associated skills deficit and co-morbidities make the management
of epilepsy particularly challenging for people with learning disabilities. The Books Beyond Words booklet for
epilepsy uses images to help people with learning disabilities manage their condition and improve quality of life.
Our aim is to conduct a randomized controlled feasibility trial exploring key methodological, design and
acceptability issues, in order to subsequently undertake a large-scale randomized controlled trial of the Books
Beyond Words booklet for epilepsy.
Methods/Design: We will use a two-arm, single-centre randomized controlled feasibility design, over a 20-month
period, across five epilepsy clinics in Hertfordshire, United Kingdom. We will recruit 40 eligible adults with learning
disabilities and a confirmed diagnosis of epilepsy and will randomize them to use either the Books Beyond Words
booklet plus usual care (intervention group) or to receive routine information and services (control group). We will
collect quantitative data about the number of eligible participants, number of recruited participants, demographic
data, discontinuation rates, variability of the primary outcome measure (quality of life: Epilepsy and Learning
Disabilities Quality of Life scale), seizure severity, seizure control, intervention’s patterns of use, use of other
epilepsy-related information, resource use and the EQ-5D-5L health questionnaire. We will also gather qualitative
data about the feasibility and acceptability of the study procedures and the Books Beyond Words booklet. Ethical
approval for this study was granted on 28 April 2014, by the Wales Research Ethics Committee 5. Recruitment
began on 1 July 2014.
Discussion: The outcomes of this feasibility study will be used to inform the design and methodology of a
definitive study, adequately powered to determine the impact of the Books Beyond Words intervention to improve
the management of epilepsy in people with learning disabilities.
Trial registration: ISRCTN80067039 (Date of ISRCTN assignation: 23 April 2014).
Keywords: Epilepsy, Learning disability, Intervention, Feasibility trial, Clinical protocol
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Background
Rationale

People with learning disabilities experience a disproportionate burden of ill health and are affected by twice the
number of health issues prevailing in the general population: higher incidence of long-term conditions and
health risks, poorer health outcomes and an increased
risk of premature death [1-4]. Epilepsy is one of many
long-term conditions affecting people with learning disabilities that burdens their lives and hinders their quality
of life [5]. It is considered the most common neurological disorder in people with learning disabilities, with
a reported prevalence of 16 to 44% [2,5-8], compared to
0.4% to 1% in the general population [9,10].
The clinical management of epilepsy in people with
learning disabilities is complex, due to both the clinical
characteristics of the condition, as well as physical and
cognitive impairments affecting them. Seizures are frequent, atypical and often severe. Approximately 70% of
all seizures are refractory to treatment [11-14]. Seizures
are less well controlled than in the general population of
people with epilepsy, and may be accompanied by comorbid health, mental health, sensory-motor and communication issues [15-17]. Poorly controlled epilepsy
can severely affect social relationships, work, daily activities, quality of life and mortality [18-20]. As a result,
young people and adults with learning disabilities and
epilepsy face higher risks of premature and avoidable
death related to epilepsy than the general population
[21]. In addition, research shows that poorly controlled
seizures and seizure frequency are associated with increased costs [22]. Pennington et al. recently demonstrated increased costs in people with epilepsy and
learning disabilities [23], with a total estimated cost per
patient, per annum, of £64,000 (including accommodation and basic care).
Managing long-term conditions is challenging for all
patients, irrespective of their abilities and co-morbidities.
However, it is even more complex for those with learning disabilities, who may not have the knowledge, skills
and support required to assess potential risks and cope
with recurring seizures, prescribed medications and
regular doctor appointments. Research suggests that access to specialist services is poor for people with epilepsy
and learning disabilities [24]. For carers and families
who are not trained in supporting self-management, caring for adults with ‘dual disabilities’ can be extremely
challenging and increase the caregiver burden [5]. Despite its high incidence, little is known about the management of epilepsy in people with learning disabilities, and
those who support them. Research suggests that people
with learning disabilities and epilepsy lack skills training
adapted to their needs and intellectual abilities, and
often fail to adequately manage and control their
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epilepsy [20]. The standard of care offered to people
with learning disabilities and epilepsy is significantly
poorer than in the general population, as is the case
for most disease areas affecting people with learning
disabilities [24,25].
Guidelines from the National Institute for Health and
Care Excellence (NICE) state that patients with epilepsy
and learning disabilities: ‘should be empowered to
manage their condition as well as possible, and should
receive appropriate information and education about all
aspects of epilepsy […] accessible to people with
additional needs such as physical, sensory or learning
disabilities’ [26]; p.9.
The Books Beyond Words booklet Getting on with
Epilepsy has been designed to help people with learning disabilities and epilepsy understand and manage
their illness through images that have been tested with
people with mild to severe learning disabilities. The
intervention is based on the assumption that people
with learning disabilities who cannot read and have
limited communication abilities are visually literate.
Although the success and impact of the Books Beyond
Words booklets (over 30 available) have been recognized by several awards and collaborations with established patient organizations, they have not as yet been
formally evaluated in controlled settings or routinely
adopted in the United Kingdom National Health Service
(NHS). The lack of conclusive data on the effectiveness
of educational interventions for people with epilepsy
and learning disabilities warrants further investigation
[24,26].
Aim

We aim to conduct a randomized controlled feasibility
trial exploring key methodological, design and acceptability issues, in order to subsequently undertake a
large-scale randomized controlled trial of the Books
Beyond Words booklet as an intervention for epilepsy in
adults with learning disabilities.
Objectives

Our objectives are to:
1. Assess the feasibility of undertaking a randomized
controlled trial of the Books Beyond Words
intervention for epilepsy in people with learning
disabilities.
2. To explore the feasibility of collecting resource use
and quality of life data so as to inform the design of
the health economics component of a future
definitive trial.
3. Assess the study procedures’ and intervention’s
acceptability among adults with learning disabilities,
carers and health professionals.
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Methods/Design
Study design and setting

We will use a two-arm, single-centre design and will conduct the study over a 20-month period at Hertfordshire
Partnership University NHS Foundation Trust, United
Kingdom. The trust runs five epilepsy clinics, managing
196 adults with learning disabilities and epilepsy. The patients are seen on average once a month. We will randomly allocate eligible participants to an intervention
arm (provision of the Books Beyond Words booklet Getting on with Epilepsy) and control arm (routine information and services), and will recruit participants over six
months.
Participants

Eligible participants will be identified by the consultant
psychiatrists who run the epilepsy clinics. Each psychiatrist will compile a log of potentially eligible patients
from existing records and from new referrals using the
following criteria.
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asked to encourage patients who have the capacity to
read and understand (or to be read to and understand)
the easy-read information sheet to do so. For patients
who lack the mental capacity to understand the information sheet, consent will be obtained from the patient’s
carer. It will be the carer’s role to use what they know of
the patient’s wishes and feelings about research to decide
whether they would like to take part in the study.
After a week, the research nurse will invite carers and
patients by phone, to attend a meeting at the epilepsy
clinic. During this appointment, the research nurse will
review the patient information sheets with both the patient and the carer, and will take consent from the patient, with the carer’s involvement and advice, using an
easy-read consent form. For patients who lack the capacity to consent, the research nurse will use a consultee
declaration form, which will be completed and signed by
the carer. The research nurse will also inform the patient’s GP of their participation in the feasibility trial.
Randomization

Inclusion criteria

The inclusion criteria for this study are as follows:
1. Male and female patients, over 18 years of age.
2. A confirmed clinical diagnosis of epilepsy (according
to medical notes) and at least one seizure over the
past 12 months.
3. A confirmed clinical diagnosis of a learning disability
(significantly below-average general intellectual
functioning, and an IQ below or equal to 70).
4. Meaningful communication that enables the patient
to tell or follow the Books Beyond Words story, as
judged by the carer and/or health professional.
5. The carer is sufficiently proficient in English to read
and complete the questionnaires with the patient.
Exclusion criteria

The exclusion criteria for this study are as follows:
1. Vision impairment.
2. Confirmed diagnosis of dementia.
3. Have used the Books Beyond Words booklet for
epilepsy in the past 12 months.

Consent
Each consultant psychiatrist at the participating epilepsy
clinics will send an invitation letter and two information
sheets to the carers of all eligible patients with learning
disabilities and epilepsy registered at the clinics. In accordance with the Mental Capacity Act 2005 [27], an
easy-read information sheet and invitation letter will be
intended for the patient and another information sheet
for the carer. In the information sheet, carers will be

During the initial appointment with the research nurse
at the epilepsy clinic, and after consent has been taken,
the carer will complete the baseline questionnaire.
Randomization will be managed by the Norwich Clinical
Trials Unit (NCTU). Once consent is obtained and the
baseline data registered, the research nurse will allocate
the patient to the intervention or control arm, as
instructed by the randomization website. All authorized
users, including the research nurse, will login using their
unique username and password to a secure website to
randomize each participant. The results will be stored in
a study database on the Norwich Clinical Trials Unit
(NCTU) secure server at the University of East Anglia
(no user identifiable data will be stored in the
randomization database). Web traffic will be encrypted
using standard secure sockets layer technology. The
randomization (1:1 allocation ratio) will be ‘blocked’ into
groups of six codes to reduce the imbalance of control
and intervention group participants at any time.
Intervention group

The Books Beyond Words booklet Getting on with Epilepsy uses pictures to tell the story of a young man with
learning disabilities and epilepsy who progressively
learns how to better manage his condition and recurrent
seizures (see Figure 1). The intervention aims to improve
seizure control, reduce the risk of falls and seizurerelated injuries and improve quality of life. It also aims
to illustrate best practice and promote access to relevant
services. The Books Beyond Words booklet for epilepsy
was developed over an 18-month period, by an editorial
team of consultants in psychiatry and neurodevelopmental psychiatry, a speech and language therapist and an
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Sheila Hollins & Lisa Kopper www.booksbeyondwords.co.uk

Figure 1 The Books Beyond Words intervention.

illustrator. They were supported by an advisory group
of medical experts in the field of epilepsy and learning disabilities, by adults with learning disabilities
and their carers, voluntary organizations and advocacy groups. Several iterations were developed and
tested with a wide group of stakeholders, including
adults with mild to severe learning disabilities and
epilepsy [28].

How the Books Beyond Words intervention will be used

After giving consent and completing the baseline questionnaires, patients in the intervention condition will use
the booklet with the research nurse and carer, in a quiet
room at the epilepsy clinic. The nurse will go through
the booklet with each patient at their own pace. Health
professionals and carers can create their own story with
the patient or use the story provided at the end of the
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booklet. The booklet contains instructions for use and a
list of useful resources and services. The research nurse
will show the first picture of the booklet to the person
with learning disabilities, who should be encouraged to
hold the book and turn the pages at their own pace. Depending on the patient’s communication abilities and reactions, it is advised that the research nurse will prompt
them to say what is happening, whether this has happened to them before, and how they feel about it. We
anticipate that it may take up to one hour to go through
the booklet. If the intervention cannot be explored in
one sitting, the research nurse will arrange a further appointment. The patient will also be given a copy to take
home and explore with the carer and/or relatives.
It is recommended that the patient is given the opportunity to use the book at least twice more at home over
the study duration. The research nurse will call each
carer two weeks after randomization to remind them
that the patient should be given opportunities to use the
booklet at least twice more. Use of the book at home
with the carer or other relatives will be monitored as
part of the follow-up assessments. The carers will not receive any formal training in using the booklet, but will
be able to watch an online video and training slides
explaining how to use the book with the person they
care for. A link to the training video and slides will be
provided by the nurse at the end of the initial meeting.
The research nurse will receive a half-day training
course in using the intervention.
Control group

Participants in the control group will receive routine information and services. The use of a picture book, such
as the Books Beyond Words intervention or other educational package, will not be part of the routine consultation. After the study has terminated, patients in the
control condition will be provided with a Books Beyond
Words booklet to use with the epilepsy nurse specialist,
the consultant and/or the carer.
Outcome measures

Each patient will be assessed at baseline (T0), and at four
(T1), 12 (T2) and 20 (T3) weeks after randomization (see
Figure 2.). We will measure the following outcomes for
both groups except where specified otherwise (see
Table 1).
Quantitative assessment

The quantitative assessment will examine the following:
1. Number of eligible patients identified and number
recruited.
2. Variability of the primary outcome quality of life,
using the Epilepsy and Learning Disabilities Quality
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3.
4.

5.
6.
7.
8.

9.

of Life (ELDQOL) scale [29,30]. The ELDQOL
consists of four subscales: behaviour, seizure
severity, mood and side effects.
Seizure control as a secondary outcome measure,
assessed using a seizure diary.
Seizure severity as a secondary outcome measure,
assessed using the seizure severity subscale of the
ELDQOL scale.
Discontinuation rates across both arms and
reasons.
Patterns of use of the Books Beyond Words booklet
(for intervention group only).
Use of other epilepsy-related information.
Resource use and health-related quality of life using
a context-specific resource use questionnaire and the
EQ-5D-5 L scale [31].
Demographic data: age, sex, ethnicity, and living
circumstances of the participant, information about
the type of care provided by the carer and
relationship to the participant.

Qualitative assessment

We will conduct semi-structured qualitative interviews
at 20 weeks post-randomization, with a random sample
of 15 patients and carers (or until data saturation), selected from both control and intervention groups, as
well as all health professionals involved in the feasibility
trial (n = 9). The semi-structured interviews will explore
the feasibility and acceptability of the recruitment procedures (such as allocation, randomization and potential
weaknesses of the design), use and perceived usefulness
of existing resources and services, information and selfmanagement support needs, perceived acceptability of
the intervention and perceived barriers and facilitators
to the use and dissemination of the intervention in routine care.
Data collection and management

Data will be collected at baseline, four, 12 and 20 weeks
post-randomization using a questionnaire and seizure
diary completed by the carer, with the patient’s involvement whenever possible. The baseline questionnaire will
be completed at the initial meeting with the research
nurse. The follow-up questionnaires will be sent to the
carer in the post and returned in a prepaid envelope. A
research fellow will follow-up on patients and carers
using the telephone at four, 12 and 20 weeks postrandomization to encourage the return of the questionnaires. A random sample of participants will also be
invited to take part in an interview at 20 weeks postrandomization.
Data management will be provided by NRTU. The webbased data entry system will be built using Microsoft
SQL Server tools. It will comply with the International
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Figure 2 Consolidated Standards of Reporting Trials (CONSORT) study flow-chart.

Conference on Harmonization of Technical Requirements
for Registration of Pharmaceuticals for Human Use
Guideline for Good Clinical Practice (GCP), and will
be restricted to authorized study team members and
NRTU staff.
Data analysis
Quantitative data

The analysis primarily aims to determine the feasibility
of undertaking a full-scale randomized controlled trial
and will seek to assess:
1. The number and demographics of eligible patients
identified, screened, consented and randomized to
each arm, and the relative performance in each
clinic.
2. The demographics of patients who are excluded
from the trial, reasons for exclusion and
estimation of the proportion of eligible patients
approached who agree to enter and complete the
trial.

3. The proportion of completed study measures in
each arm, measured from baseline to the last
follow-up assessment.
4. The proportion of patients withdrawing from the
study, measured from baseline to the last follow-up
assessment.
5. The variation in the primary outcome measure that
will be used, following Cocks and Torgerson [32], to
determine whether a one-sided 80% confidence
interval would exclude a 10% increase in the primary
outcome (ELDQOL).
6. The frequency of use of the Books Beyond Words
intervention, and other sources of information
before and after randomization, and the extent to
which use of the Books Beyond Words booklet
influences outcome and other information
resource use.
In parallel, a health economic assessment will be undertaken. We will monitor levels of resource-use and
quality of life to inform the decision as to how costs and
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Table 1 Study procedures according to study schedule
Study procedures

Study period
Enrollment

Randomization
T0

Eligibility screen

X

Informed consent

X

Post-randomization
T1 week 4

T2 week 12

T3 week 20

Allocation

X

Intervention

X

Rates of recruitment

X

X

X

X

Quality of life (Epilepsy and Learning Disabilities Quality of Life,
ELDQOL. scale)

X

X

X

X

Demographic data

X

Seizure severity (using ELDQOL Seizure Severity Scale)

X

Seizure control (diary cards)

X

X

X

X

Feasibility and acceptability (qualitative interviews)

X

Resource use

X

Quality of life (EQ-5D-5L scale)

X

benefits should be measured as part of a future, more
definitive study. NICE guidance recommends that costs
are calculated from the perspective of the NHS and Personal Social Services (PSS) [33]. We will thereby seek to
monitor levels of resource-use associated with the epilepsy booklet and the use of other NHS and PSS
resource-items. Appropriate unit costs will subsequently
be attached to all items of resource-use, to estimate the
mean overall cost in each study-arm [34]. In line with
NICE guidance, the EQ-5D [35] will be used to assess
the effectiveness of each option. This will enable the
quality-adjusted life year gain to be estimated. All analyses will be reported according to relevant CONSORT
standards [36].

X
X

X

X

be targeted. However, the study team, the selected study
design and recruitment procedures will aim to minimize
all potential dropouts whenever possible.
Recent audit data indicates that there were 196 patients
with epilepsy and learning disabilities registered at the
Hertfordshire Partnership University NHS Foundation
Trust in May 2013. A preliminary screening exercise has
already been undertaken by the lead consultant psychiatrist, at each epilepsy clinic, confirming that 112 out of
196 patients meet the study’s inclusion criteria. This does
not include new referrals, who will be screened for eligibility once recruitment commences. The study will therefore
aim to recruit approximately 36% of eligible patients.
Confidentiality

Qualitative data

The data collected in the semi-structured interviews will
be analyzed using a two-step thematic content analysis
derived from descriptive phenomenology [37,38], assisted
by the computer software NVivo.
Sample size and feasibility of recruitment

The present study aims to assess the variation in the primary outcome measure between groups from baseline to
the 12-week follow-up assessment, in order to determine
whether the intervention is likely to achieve a 10% increase in the participants’ quality of life [32]. This would
equate to an effect size of approximately 0.4, requiring a
total sample size of 174 in a full study (1-β = 0.8, α =
0.05). Based on the requirement of 9% of the total sample size in each group, this indicates a required sample
size of 16 per group, and will enable the exclusion of an
effect size of <0. Given a potential 25% dropout rate, a
sample size of 20 per group (40 participants in total) will

This study will be conducted in accordance with the
Data Protection Act 1998 [39] and the guidelines of the
Declaration of Helsinki 1964 (updated Tokyo 2004) [40].
Access to the screening and randomization log, containing patient-identifiable data, will be restricted to authorized personnel and will be password-protected. Only
GCP certified investigators approved by the Trial Steering Committee will be able to access the data. A unique
patient identification number will be generated by the
study web-based data entry system for each new patient
entered in the system by the research nurse. This ensures anonymized data. A sequential number, starting at
001, will be generated for each new patient consented
and entered into the study by the research nurse.
The original signed consent forms will be retained at
the study site, in a locked cabinet. After all participants
have been recruited, the researcher will collect baseline
questionnaires from the epilepsy clinics. All case report
forms and signed consent forms will be collected at the
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end of the study and stored in a locked cabinet at the
University of Hertfordshire. Patient data relating to the
study will be deleted or destroyed within three months
of the end of the study. Anonymized study data will be
archived by the University of Hertfordshire for five years
after study completion, in line with standard research
protocols. Investigators will not disclose patient data in
any form to anyone not involved directly in the study.
All electronic data will be stored on password-protected
computers, and paper files will be stored in locked filing
cabinets, both of which will be kept within electronically
locked offices.
Ethical considerations

This study includes people with learning disabilities who
may or may not lack the capacity to consent. Whenever
possible, consent will be obtained from the patient, with
the carer’s involvement and advice, who will assess the
participants’ capacity to take part, as required by the
Mental Capacity Act. For patients who have the capacity
to read or be read to and understand simple information
(as determined by the carer and research nurse), an
easy-read information sheet and invitation letter will be
provided. These have been specifically designed according to the principles of the Mental Capacity Act (2005)
[27], guidance from the Department of Health on producing easy-read information and guidance from the National Ethics Service on the design of study materials for
adults without capacity. The information is paced, carefully structured, using simple language and images and
with frequent references made to the carer. The easyread consent form, invitation letter and information
sheet have been reviewed by people from Hertfordshire
Partnership University Foundation Trust, specializing in
the development of easy-read information, and by members of our reference group, including people with learning disabilities, carers and members of the public. For
patients who lack the capacity to consent, carers will be
asked to complete and sign a consultee declaration form.
Ethical approval for this study was granted on 28 April
2014, by the Wales Research Ethics Committee 5 (reference: 14/WA/0135).

Discussion
This study is the first to assess the feasibility of undertaking a randomized controlled trial of an image-centric
intervention, designed to facilitate the management of
epilepsy in people with learning disabilities. The outputs
of this feasibility study will be used to inform the design
and methodology of a definitive study, adequately powered to determine the impact of the Books Beyond
Words intervention to improve the management of epilepsy in people with learning disabilities. As advocated
by NICE, The Royal College of General Practitioners and
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the Learning Disabilities Observatory, improving disease
management and access to services of people with learning disabilities and epilepsy is essential and should
become a priority in routine care. Although the feasibility study will not demonstrate whether or not Books Beyond Words interventions can achieve those goals, and
provide value for money, this will be addressed by the
definitive trial. The results will therefore have significant
and long-lasting implications for clinical practice and
service delivery, whereby Books Beyond Words interventions could become routinely embedded in the NHS,
yielding significant benefits for patients, their carers and
the wider population.
Further, the results of the feasibility trial will be of
utmost importance to patient groups and clinicians in
raising awareness of emerging research in learning disabilities and epilepsy, and demonstrating the potential
acceptability of this intervention. Dissemination of the
results will primarily be achieved through publication in
peer-reviewed scientific journals, and reports intended
for people with learning disability, their carers, families
and the wider lay community, disseminated through national and local patient networks, including the Making
it Better Group, Inclusion East, and the British Institute
of Learning Disabilities (BILD). Promoting the involvement of people with learning disabilities in research and
demonstrating potential benefits will be another focus of
our dissemination strategy. We will work closely with
the BILD and with the Patient Involvement in Research
Group to raise awareness and increase the representation of patients with learning disabilities and their carers
in research.

Trial status
The trial set-up phase was completed at the end of May
2014. Recruitment started on 1 July 2014 and is expected to end in March 2015.
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